ERBB2 and Langer mesomelic dysplasia: Similarly, a prospective study of 26 patients with human epidermal growth factor receptor 2-positive (HER2-positive) leptomeningeal disease (LMD) treated with 80 mg of intrathecal trastuzumab has reported an OS of 10.5 months [115].